{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:38:23Z","timestamp":1786365503366,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40261-023-01261-y","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:03:15Z","timestamp":1683900195000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Improving Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction: New Evidence from Clinical Trials to Real Life"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0644-0560","authenticated-orcid":false,"given":"Fedor","family":"Lurie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daciana E.","family":"Branisteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"2","key":"1261_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.suc.2017.11.002","volume":"98","author":"JD Raffetto","year":"2018","unstructured":"Raffetto JD. Pathophysiology of chronic venous disease and venous ulcers. Surg Clin N Am. 2018;98(2):337\u201347. https:\/\/doi.org\/10.1016\/j.suc.2017.11.002.","journal-title":"Surg Clin N Am."},{"issue":"5","key":"1261_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ejvs.2018.02.009","volume":"55","author":"C das Gra\u00e7as","year":"2018","unstructured":"das Gra\u00e7as C, de Souza M, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg. 2018;55(5):694\u2013702. https:\/\/doi.org\/10.1016\/j.ejvs.2018.02.009.","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"5","key":"1261_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.23736\/S0392-9590.21.04726-X","volume":"40","author":"FZ Cyrino","year":"2021","unstructured":"Cyrino FZ, Blanc-Guillemaud V, Bouskela E. Time course of microvalve pathophysiology in high pressure low flow model of venous insufficiency and the role of micronized purified flavonoid fraction. Int Angiol. 2021;40(5):388\u201394. https:\/\/doi.org\/10.23736\/S0392-9590.21.04726-X.","journal-title":"Int Angiol."},{"issue":"3","key":"1261_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jvsv.2019.12.075","volume":"8","author":"F Lurie","year":"2020","unstructured":"Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342\u201352. https:\/\/doi.org\/10.1016\/j.jvsv.2019.12.075.","journal-title":"J Vasc Surg Venous Lymphat Disord."},{"key":"1261_CR5","unstructured":"Lugli M, Longhi M, Guerzoni S, Maleti O. Effect of micronized purified flavonoid fraction treatment on microscopic venous valves reflus in C0s and C1s patients with chronic venous disease [P24]. In: 21st virtual European venous forum meeting; 24\u201326 June 2021; virtual."},{"issue":"2","key":"1261_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.23736\/S0392-9590.18.03901-9","volume":"37","author":"M Lugli","year":"2018","unstructured":"Lugli M, Maleti O, Iabichella ML, Perrin M. Investigation of non-saphenous veins in C0S patients. Int Angiol. 2018;37(2):169\u201375. https:\/\/doi.org\/10.23736\/S0392-9590.18.03901-9.","journal-title":"Int Angiol."},{"issue":"3","key":"1261_CR7","first-page":"144","volume":"24","author":"YT Tsukanov","year":"2017","unstructured":"Tsukanov YT, Tsukanov AY. Diagnosis and treatment of situational great saphenous vein reflux in daily medical practice. Phlebolymphology. 2017;24(3):144\u201351.","journal-title":"Phlebolymphology."},{"issue":"1","key":"1261_CR8","first-page":"42","volume":"29","author":"N Khorev","year":"2022","unstructured":"Khorev N, Kuznetsova D. Pharmacological correction of total venous reflux in patients with varicose veins. Phlebolymphology. 2022;29(1):42\u20136.","journal-title":"Phlebolymphology."},{"issue":"6","key":"1261_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000179078","volume":"15","author":"E Bouskela","year":"1995","unstructured":"Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia\/reperfusion in diabetic hamsters. Int J Microcirc Clin Exp. 1995;15(6):293\u2013300. https:\/\/doi.org\/10.1159\/000179078.","journal-title":"Int J Microcirc Clin Exp."},{"issue":"1","key":"1261_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/000331979704800108","volume":"48","author":"V Ibegbuna","year":"1997","unstructured":"Ibegbuna V, Nicolaides AN, Sowade O, Leon M, Geroulakos G. Venous elasticity after treatment with Daflon 500 mg. Angiology. 1997;48(1):45\u20139. https:\/\/doi.org\/10.1177\/000331979704800108.","journal-title":"Angiology"},{"issue":"5","key":"1261_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ejvs.2004.05.012","volume":"28","author":"S Takase","year":"2004","unstructured":"Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Sch\u00f6nbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg. 2004;28(5):484\u201393. https:\/\/doi.org\/10.1016\/j.ejvs.2004.05.012.","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"1","key":"1261_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejvs.2007.08.011","volume":"35","author":"L Pascarella","year":"2008","unstructured":"Pascarella L, Lulic D, Penn AH, et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. Eur J Vasc Endovasc Surg. 2008;35(1):102\u201310. https:\/\/doi.org\/10.1016\/j.ejvs.2007.08.011.","journal-title":"Eur J Vasc Endovasc Surg."},{"key":"1261_CR13","first-page":"397","volume":"49","author":"FZ Cyrino","year":"2005","unstructured":"Cyrino FZ, Bottino DA, Bouskela E. Protection of the microcirculation during ischemia\/reperfusion is enhanced by micronization of purified flavonoid fraction. Phlebolymphology. 2005;49:397\u2013402.","journal-title":"Phlebolymphology."},{"issue":"2","key":"1261_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejvs.2014.05.017","volume":"48","author":"LA Robertson","year":"2014","unstructured":"Robertson LA, Evans CJ, Lee AJ, Allan PL, Ruckley CV, Fowkes FG. Incidence and risk factors for venous reflux in the general population: Edinburgh Vein Study. Eur J Vasc Endovasc Surg. 2014;48(2):208\u201314. https:\/\/doi.org\/10.1016\/j.ejvs.2014.05.017.","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"2","key":"1261_CR15","first-page":"70","volume":"27","author":"VY Bogachev","year":"2020","unstructured":"Bogachev VY. Effectiveness of micronized purified flavonoid fraction-based conservative treatment in chronic venous edema. Phlebolymphology. 2020;27(2):70\u201380.","journal-title":"Phlebolymphology."},{"issue":"4","key":"1261_CR16","first-page":"310","volume":"31","author":"FA Allaert","year":"2012","unstructured":"Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012;31(4):310\u20135.","journal-title":"Int Angiol"},{"issue":"2","key":"1261_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.23736\/S0392-9590.18.03975-5","volume":"37","author":"SK Kakkos","year":"2018","unstructured":"Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon\u00ae) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143\u201354. https:\/\/doi.org\/10.23736\/S0392-9590.18.03975-5.","journal-title":"Int Angiol."},{"issue":"2","key":"1261_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejvs.2005.04.017","volume":"30","author":"P Coleridge-Smith","year":"2005","unstructured":"Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30(2):198\u2013208. https:\/\/doi.org\/10.1016\/j.ejvs.2005.04.017.","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"3","key":"1261_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.23736\/S0392-9590.18.03999-8","volume":"37","author":"A Nicolaides","year":"2018","unstructured":"Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181\u2013254. https:\/\/doi.org\/10.23736\/S0392-9590.18.03999-8.","journal-title":"Int Angiol."},{"issue":"2","key":"1261_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejvs.2021.12.024","volume":"63","author":"MG de Maeseneer","year":"2022","unstructured":"de Maeseneer MG, Kakkos SK, Aherne T, et al. Editor\u2019s choice\u2014European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184\u2013267. https:\/\/doi.org\/10.1016\/j.ejvs.2021.12.024.","journal-title":"Eur J Vasc Endovasc Surg."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01261-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T15:07:13Z","timestamp":1685113633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01261-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":20,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01261-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"23 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has been published as a part of a journal supplement wholly funded by Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"This article is based on a presentation given during a symposium funded by Servier.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors received an honorarium from Servier for their participation in the symposium, and have other no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors contributed to the conception, drafts, and final version of this article, and gave approval of the version to be published.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}